This may also reflect better post-discharge care, with implementation of guideline-directed medical therapy for conditions such as heart failure, myocardial infarction, and arrhythmias using beta-blockers, angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, and implantable devices when appropriate. The gene discussed is SLC5A2; the disease is myocardial infarction.